PTC Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- PTC Therapeutics's estimated annual revenue is currently $492.2M per year.
- PTC Therapeutics's estimated revenue per employee is $327,498
- PTC Therapeutics's total funding is $568M.
- PTC Therapeutics's current valuation is $3.1B. (January 2022)
Employee Data
- PTC Therapeutics has 1503 Employees.
- PTC Therapeutics grew their employee count by -15% last year.
PTC Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Sr. VP, Pharmacology and Biomarkers | Reveal Email/Phone |
2 | CFO | Reveal Email/Phone |
3 | Chief Staff to the CEO | Reveal Email/Phone |
4 | Chief Staff to the CFO | Reveal Email/Phone |
5 | Chief Staff to the Chief Business Officer | Reveal Email/Phone |
6 | CEO | Reveal Email/Phone |
7 | Chief Staff to the CIO | Reveal Email/Phone |
8 | Chief Staff and Commercial Operations EMEA | Reveal Email/Phone |
9 | CEO | Reveal Email/Phone |
10 | Executive Director, Corporate Accounting | Reveal Email/Phone |
PTC Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $8.5M | 55 | -21% | N/A | N/A |
#2 | $0.2M | 1 | 0% | N/A | N/A |
#3 | $8.5M | 55 | -29% | N/A | N/A |
#4 | $108.5M | 500 | 2% | N/A | N/A |
#5 | $0.8M | 5 | 0% | N/A | N/A |
#6 | $0.6M | 4 | 0% | N/A | N/A |
#7 | $14.7M | 68 | -23% | $206.4M | N/A |
#8 | $492.2M | 1503 | -15% | $568M | N/A |
#9 | $1.1M | 7 | -42% | N/A | N/A |
#10 | $4.5M | 29 | 0% | N/A | N/A |
What Is PTC Therapeutics?
PTC Therapeutics, Inc. discovers and develops small molecule drugs by applying its integrated RNA biology and chemistry platforms. PTC's compounds modulate gene expression by selectively binding to either RNA targets or proteins that interact with RNA. This approach has progressed the Company's drug discovery programs rapidly from targets to lead optimization. PTC's pipeline includes programs in infectious diseases, oncology, inflammation, and genetic disorders.
keywords:N/A
$568M
Total Funding
1503
Number of Employees
$492.2M
Revenue (est)
-15%
Employee Growth %
$3.1B
Valuation
N/A
Accelerator
PTC Therapeutics News
SOUTH PLAINFIELD, N.J., April 19, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference...
PTC Therapeutics, Inc. (NASDAQ:PTCT) Expected to Announce Quarterly Sales of $145.24 Million. Posted by admin on Apr 18th, 2022.
About PTC Therapeutics, Inc. PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and...
SOUTH PLAINFIELD, N.J., Oct. 25, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Brazilian National Health Surveillance Agency, ANVISA (Agência Nacional de Vigilância Sanitária), has approved the expansion of the indication of Translarna™ (ataluren) to include ...
SOUTH PLAINFIELD, N.J., Oct. 11, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Tegsedi® (inotersen) has successfully received Category 1 classification from Câmara de Regulação do Mercado de Medicamentos - CMED (Drug Market Regulation Chamber) in Brazil. Categor ...
Other Companies in South Plainfield
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $665.4M | 3278 | 7% | N/A |